Hostname: page-component-78c5997874-mlc7c Total loading time: 0 Render date: 2024-11-05T14:46:04.713Z Has data issue: false hasContentIssue false
  • English
  • Français

Under-reporting of drug use among individuals with schizophrenia: prevalence and predictors

Published online by Cambridge University Press:  03 April 2013

A. L. Bahorik ,
C. E. Newhill ,
C. C. Queen  and
S. M. Eack
A. L. Bahorik*
Affiliation:
School of Social Work, University of Pittsburgh, PA, USA Western Psychiatric Institute and Clinic, University of Pittsburgh, PA, USA
C. E. Newhill
Affiliation:
School of Social Work, University of Pittsburgh, PA, USA
C. C. Queen
Affiliation:
School of Social Work, University of Pittsburgh, PA, USA
S. M. Eack
Affiliation:
School of Social Work, University of Pittsburgh, PA, USA Western Psychiatric Institute and Clinic, University of Pittsburgh, PA, USA
*
* Address for correspondence: A. L. Bahorik, M. S. W., 3811 O'Hara Street, Webster Hall Suite 150, Pittsburgh, PA 15213, USA. (Email: [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Illicit drug use is common in individuals with schizophrenia, and it has been suspected that many individuals under-report their use of substances, leading to significant barriers to treatment. This study sought to examine the degree to which individuals with schizophrenia disclose their use of drugs on self-rated assessments, compared to laboratory assays, and to determine the contributors of under-reported drug use in this population.

Method

A total of 1042 individuals with schizophrenia who participated in screening/baseline procedures for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) completed self-rated assessments of substance use and laboratory drug testing. Laboratory tests assayed cannabis, cocaine and methamphetamine use; the procedures included radioimmunoassay (RIA) and urine drug screens.

Results

A significant proportion of participants tested positive for drug use on laboratory measures (n = 397; 38%), and more than half (n = 229; 58%) did not report using these drugs. Logistic regression models confirmed that patients who were most likely to conceal their use tended to be older, and presented with greater neurocognitive deficits. Patients who accurately reported drug use tended to have greater involvement with the criminal justice system. Illness severity and psychopathology were not associated with whether patients disclosed drug use.

Conclusions

Rates of under-reported drug use are considerable among individuals with schizophrenia when compared to laboratory assays, and the exclusive reliance on self-rated assessments should be used with caution. Patients who under-report their drug use are more likely to manifest neurocognitive deficits, which could be improved by interventions attempting to optimize treatment.

Keywords

Neurocognitionradioimmunoassay of hairschizophreniaself-report drug use assessmenturine drug screen
Type
Original Articles
Information
Psychological Medicine , Volume 44 , Issue 1 , January 2014 , pp. 61 - 69
Copyright
Copyright © Cambridge University Press 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Baumgartner, W, Hill, V, Blahd, W (1989). Hair analysis for drug of abuse. Journal of Forensic Sciences 34, 1433–1453.CrossRefGoogle Scholar
Bell, M, Milstein, R, Beam-Goulet, J, Lysaker, P, Cicchetti, D (1992). The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale: reliability, comparability, and predictive validity. Journal of Nervous and Mental Disease 180, 723–728.Google Scholar
Carey, K, Correia, C (1998). Severe mental illness and addictions: assessment considerations. Addictive Behaviors 23, 735–748.Google Scholar
Degenhardt, L, Hall, W (2001). The association between psychosis and problematic drug use among Australian adults: findings from the National Survey of Mental Health and Well-Being. Psychological Medicine 31, 659–668.CrossRefGoogle ScholarPubMed
Dixon, L (1999). Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophrenia Research 35, S93–S100.CrossRefGoogle ScholarPubMed
Dixon, L, Haas, G, Dulit, R, Weiden, P, Sweeney, J, Hien, D (1989). Substance abuse in schizophrenia: preferences, predictors, and psychopathology. Schizophrenia Research 2, 6.Google Scholar
Dixon, L, Haas, G, Weiden, P, Sweeney, J, Frances, A (1990). Acute effects of drugs abuse in schizophrenic patients: clinical observations and patients' self-report. Schizophrenia Bulletin 16, 69–79.Google Scholar
Dixon, L, Haas, G, Weiden, P, Sweeney, J, Frances, A (1991). Drug abuse in schizophrenic patients: clinical correlates and reasons for use. American Journal of Psychiatry 148, 224–230.Google Scholar
Drake, R, Mueser, K (2001). Managing comorbid schizophrenia and substance abuse. Current Psychiatry Reports 3, 418–422.Google Scholar
Eack, S, Greenwald, D, Hogarty, S, Cooley, S, DiBarry, A, Montrose, D, Keshavan, M (2009). Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial. Psychiatric Services 60, 1468–1476.CrossRefGoogle ScholarPubMed
First, M, Spitzer, R, Gibbon, M, Williams, J (1996). Structured Clinical Interview for Axes I and II DSM-IV Disorders – Patient Edition (SCID-I/P). Biometrics Research Department, New York State Psychiatric Institute: New York.Google Scholar
Fowler, I, Carr, V, Carter, N, Lewin, T (1998). Patterns of current and lifetime substance use in schizophrenia. Schizophrenia Bulletin 24, 443–455.CrossRefGoogle ScholarPubMed
Galletly, C, Field, C, Prior, M (1993). Urine drug screening of patients admitted to a state psychiatric hospital. Hospital Community Psychiatry 44, 587–589.Google ScholarPubMed
Green, M, Kern, R, Heaton, R (2004 b). Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophrenia Research 72, 41–51.Google Scholar
Green, M, Nuechterlein, J, Barch, D, Cohen, J, Essock, S, Fenton, W, Frese, F, Goldberg, T, Heaton, R, Keefe, R, Kern, R, Kraemer, H, Stover, E, Weinberger, D, Zalcman, S, Marder, S (2004 b). Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS Conference to Select Cognitive Domains and Test Criteria. Biological Psychiatry 56, 301–307.Google Scholar
Gregg, L, Barrowclough, C, Haddock, G (2006). Increased substance use in psychosis. Clinical Psychology Review 27, 494–510.CrossRefGoogle Scholar
Hjorthøj, CR, Hjorthøj, AR, Nordentoft, M (2012). Validity of Timeline Follow-Back for self-reported use of cannabis and other illicit substances – systematic review and meta-analysis. Addictive Behaviors 37, 225–233.Google Scholar
Kavanagh, DJ, Waghorn, G, Jenner, L, Chant, DC, Carr, V, Evans, M (2004). Demographic and clinical correlates of comorbid substance use disorders in psychosis: multivariate analyses from an epidemiological sample. Schizophrenia Research 66, 115–124.CrossRefGoogle ScholarPubMed
Kay, S, Fiszbein, A, Opler, L (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261–227.Google Scholar
Keefe, R, Mohs, R, Bilder, R, Harvey, P, Green, M, Meltzer, H, Gold, J, Sano, M (2003). Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophrenia Bulletin 29, 45–55.Google Scholar
Kessler, RC (2004). The epidemiology of dual diagnosis. Biological Psychiatry 54, 730–737.CrossRefGoogle Scholar
Kline, J, Stphen, KC, Schittini, M, Levin, B, Susser, M (1997). Cocaine use during pregnancy: sensitive detection by hair assay. American Journal of Public Health 87, 352–358.CrossRefGoogle ScholarPubMed
Ledgerwood, DM, Goldberger, BA, Risk, NK, Lewis, NK, Rumi, KP (2008). Comparison between self-report and hair analysis of illicit drug use in a community sample of middle-aged men. Addictive Behaviors 33, 1131–1139.CrossRefGoogle Scholar
Lehman, A, Steinwachs, D (1998). Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophrenia Bulletin 24, 1–10.Google Scholar
Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, Keefe, RS, Davis, SM, Davis, CE, Lebowitz, BD, Severe, J, Hsiao, JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209–1223.CrossRefGoogle ScholarPubMed
Magura, S, Freeman, R, Siddiqi, Q, Lipton, D (1992). The validity of hair analysis for detecting cocaine and heroin use among addicts. International Journal of the Addictions 27, 51–69.CrossRefGoogle ScholarPubMed
McEvoy, JP, Apperson, LJ, Appelbaum, PS, Ortlip, P, Brecosky, J, Hammill, K, Geller, JL, Roth, L (1989). Insight in schizophrenia. Its relationship to acute psychopathology. Journal of Nervous and Mental Disease 177, 43–47.Google Scholar
Mieczkowski, T, Barzelay, D, Gropper, B (1991). Concordance of three measures of cocaine use in an arrestee population: hair, urine, and self-report. Journal of Psychoactive Drugs 23, 241–249.CrossRefGoogle Scholar
Mieczkowski, T, Newel, R (1993). Comparing hair and urine assays for cocaine and marijuana. Federal Probation 57, 59–67.Google Scholar
Møller, T, Linaker, O (2010). Using brief self-reports and clinician scales to screen for substance use disorders in psychotic patients. Nordic Journal of Psychiatry 64, 130–135.Google Scholar
Nuechterlein, KH, Green, MF, Kern, RS, Baade, LE, Barch, DM, Cohen, JD, Essock, S, Fenton, WS, Frese, FJ 3rd, Gold, JM, Goldberg, T, Heaton, RK, Keefe, RS, Kraemer, H, Mesholam-Gately, R, Seidman, LJ, Stover, E, Weinberger, DR, Young, AS, Zalcman, S, Marder, SR (2008). The MATRICS Consensus Cognitive Battery, Part 1: Test selection, reliability and validity. American Journal of Psychiatry 165, 203–213.CrossRefGoogle ScholarPubMed
Pragst, F, Balikova, M (2006). State of the art in hair analysis for detection of drug and alcohol abuse. Clinica Chimica Acta 370, 17–49.Google Scholar
Rabin, RA, Zakzanis, KK, George, TP (2011). The effects of cannabis use on neurocognition in schizophrenia: a meta-analysis. Schizophrenia Research 128, 111–116.Google Scholar
Reiger, D, Farmer, M, Rae, D, Locke, B, Keith, S, Judd, L, Goodwin, F (1990). Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemologic Catchment Area (ECA) Study. Journal of the American Medical Association 264, 2511–2518.CrossRefGoogle Scholar
Reimherr, F, Swartz, M, Olsen, J (2010). Substance use in persons with schizophrenia: incidence, baseline correlates, and effects on outcome. In Antipsychotic Trials in Schizophrenia (ed. Stroup, S. T. and Liberman, J. A.), pp. 189–206. Cambridge University Press: New York.CrossRefGoogle Scholar
Schiffer, B, Bernhard, B, Scherbaum, N, Forsting, M, Wiltfang, J, Leygraf, N, Gizewski, E (2010). Impulsivity-related brain volume deficits in schizophrenia-addiction comorbidity. Brain 133, 3093–3103.Google Scholar
Shaner, A, Khalsa, M, Roberts, L, Wilkins, D, Hsieh, S (1993). Unrecognized cocaine use among schizophrenic patients. American Journal of Psychiatry 150, 758–762.Google ScholarPubMed
Stone, AM, Greenstein, RA, Gamble, G, McLellan, AT (1993). Cocaine use by schizophrenic outpatients who receive depot neuroleptic medication. Hospital Community Psychiatry 44, 176–177.Google ScholarPubMed
Stroup, T, McEvoy, J, Swartz, M, Byerly, M, Blick, I, Canive, J, McGee, M, Simpson, G, Stevens, M, Liberman, J (2003). The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophrenia Bulletin 29, 15–31.Google Scholar
Swartz, M, Swanson, J, Hannon, M (2003). Detection of illicit substance use among persons with schizophrenia. Psychiatric Services 54, 891–895.Google Scholar
Swartz, M, Wagner, H, Swanson, J, Stroup, S, McEvoy, J, Canive, J, Miller, D, Reimherr, F, McGee, M, Khan, A, Van Dorn, R, Rosenheck, R, Liberman, J (2006 a). Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. Journal of Nervous and Mental Disease 194, 164–172.CrossRefGoogle ScholarPubMed
Swartz, M, Wagner, H, Swanson, J, Stroup, S, McEvoy, J, McGee, M, Miller, D, Reimherr, F, Khan, A, Canive, J, Liberman, J (2006 b). Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. Psychiatric Services 57, 1110–1116.CrossRefGoogle ScholarPubMed
Van Dorn, R, Desmarais, S, Young, S, Sellers, B, Swartz, M (2012). Assessing illicit drug use among adults with schizophrenia. Psychiatry Research 200, 228–236.CrossRefGoogle ScholarPubMed
Verstraete, A (2004). Detection times of drugs of abuse in blood urine, an oral fluid. Therapeutic Drug Monitoring 26, 200–205.CrossRefGoogle ScholarPubMed
Vincenti, A, Ventrigilo, A, Baldessarini, R, Talamo, A, Fitzmaurico, G, Centorrino, F (2010). Characteristics and clinical changes during hospitalization in bipolar and psychiatric disorder patients with and without substance use disorders. Pharmacopsychiatry 43, 225–232.Google Scholar
Volkow, N (2009). Substance use disorders in schizophrenia – clinical implications of comorbidity. Schizophrenia Bulletin 35, 469–472.CrossRefGoogle ScholarPubMed
Weiss, R, Najavits, L, Greenfield, S, Soto, J, Shaw, S, Wyner, D (1998). Validity of substance use self-reports in dually diagnosed outpatients. American Journal of Psychiatry 155, 127–128.Google Scholar
Welch, M, Sniegoski, L, Allgood, C, Habram, M (1993). Hair analysis for drugs of abuse: evaluation of analytical methods. Environmental issues and development of reference materials. Journal of Analytical Toxicology 17, 389–398.Google Scholar
Woods, S (2003). Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry 64, 663–667.Google Scholar
Yücel, M, Bora, E, Lubman, D, Solowij, N, Brewer, W, Cotton, S, Conus, P, Takagi, M, Fornito, A, Wood, S, McGorry, P, Pantelis, C (2010). The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophrenia Bulletin 38, 316–330.Google Scholar
Zedonis, D, Smelson, D, Rosenthal, R, Batki, S, Green, A, Henry, R, Montoya, I, Parks, J, Weiss, R (2005). Improving the care of individuals with schizophrenia and substance use disorders. Consensus recommendations. Journal of Psychiatric Practice 1, 315–339.Google Scholar